Merrimack Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 52 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Merrimack Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Merrimack Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Merrimack Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Merrimack Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Merrimack Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Merrimack Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Merrimack Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

- Evaluate Merrimack Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Merrimack Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Merrimack Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Merrimack Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Merrimack Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Merrimack Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Merrimack Pharmaceuticals, Inc. Snapshot 5
Merrimack Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Merrimack Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Merrimack Pharmaceuticals, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Merrimack Pharmaceuticals, Inc. - Pipeline Products Glance 13
Merrimack Pharmaceuticals, Inc. - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
Merrimack Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Merrimack Pharmaceuticals, Inc. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Merrimack Pharmaceuticals, Inc. - Drug Profiles 17
irinotecan sucrosofate liposomal 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
MM-111 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
MM-121 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
MM-141 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
MM-151 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
MM-302 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
MM-131 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
MM-310 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Merrimack Pharmaceuticals, Inc. - Pipeline Analysis 29
Merrimack Pharmaceuticals, Inc. - Pipeline Products by Target 29
Merrimack Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 31
Merrimack Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 32
Merrimack Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 33
Merrimack Pharmaceuticals, Inc. - Recent Pipeline Updates 35
Merrimack Pharmaceuticals, Inc. - Dormant Projects 49
Merrimack Pharmaceuticals, Inc. - Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Tables
Merrimack Pharmaceuticals, Inc., Key Information 5
Merrimack Pharmaceuticals, Inc., Key Facts 5
Merrimack Pharmaceuticals, Inc. - Pipeline by Indication, 2014 7
Merrimack Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9
Merrimack Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10
Merrimack Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 11
Merrimack Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12
Merrimack Pharmaceuticals, Inc. - Phase III, 2014 13
Merrimack Pharmaceuticals, Inc. - Phase II, 2014 14
Merrimack Pharmaceuticals, Inc. - Phase I, 2014 15
Merrimack Pharmaceuticals, Inc. - Preclinical, 2014 16
Merrimack Pharmaceuticals, Inc. - Pipeline by Target, 2014 30
Merrimack Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 31
Merrimack Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 32
Merrimack Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 34
Merrimack Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 35
Merrimack Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 49
Merrimack Pharmaceuticals, Inc., Subsidiaries 50